Dupilumab, a fully human anti–IL-4α receptor monoclonal antibody, inhibits IL-4 and IL-13 and appears to be effective in patients with moderate to severe asthma, regardless of baseline serum eosinophil counts [73]. This evidence concerns the gene IL13 and asthma.